202 related articles for article (PubMed ID: 31219148)
21. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
22. Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia.
Alraddadi BM; Heaphy ELG; Aljishi Y; Ahmed W; Eljaaly K; Al-Turkistani HH; Alshukairi AN; Qutub MO; Alodini K; Alosaimi R; Hassan W; Attalah D; Alswaiel R; Saeedi MF; Al-Hamzi MA; Hefni LK; Almaghrabi RS; Anani M; Althaqafi A
BMC Infect Dis; 2022 Jun; 22(1):542. PubMed ID: 35698046
[TBL] [Abstract][Full Text] [Related]
23. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
24. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
[TBL] [Abstract][Full Text] [Related]
25. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
26. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.
Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R
Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423
[TBL] [Abstract][Full Text] [Related]
27. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
Gutiérrez-Gutiérrez B; Salamanca E; de Cueto M; Hsueh PR; Viale P; Paño-Pardo JR; Venditti M; Tumbarello M; Daikos G; Cantón R; Doi Y; Tuon FF; Karaiskos I; Pérez-Nadales E; Schwaber MJ; Azap ÖK; Souli M; Roilides E; Pournaras S; Akova M; Pérez F; Bermejo J; Oliver A; Almela M; Lowman W; Almirante B; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J;
Lancet Infect Dis; 2017 Jul; 17(7):726-734. PubMed ID: 28442293
[TBL] [Abstract][Full Text] [Related]
28. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
29. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
30. Bloodstream infections caused by Klebsiella pneumoniae: prevalence of bla
Xu M; Fu Y; Kong H; Chen X; Chen Y; Li L; Yang Q
BMC Infect Dis; 2018 Jul; 18(1):358. PubMed ID: 30064360
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
33. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
[TBL] [Abstract][Full Text] [Related]
34. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
[TBL] [Abstract][Full Text] [Related]
35. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
36. Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections.
Gallagher JC; Kuriakose S; Haynes K; Axelrod P
Antimicrob Agents Chemother; 2014 Oct; 58(10):5732-5. PubMed ID: 25022587
[TBL] [Abstract][Full Text] [Related]
37. Derivation of a quick Pitt bacteremia score to predict mortality in patients with Gram-negative bloodstream infection.
Battle SE; Augustine MR; Watson CM; Bookstaver PB; Kohn J; Owens WB; Baddour LM; Al-Hasan MN
Infection; 2019 Aug; 47(4):571-578. PubMed ID: 30737765
[TBL] [Abstract][Full Text] [Related]
38. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections.
Viale P; Giannella M; Lewis R; Trecarichi EM; Petrosillo N; Tumbarello M
Expert Rev Anti Infect Ther; 2013 Oct; 11(10):1053-63. PubMed ID: 24073806
[TBL] [Abstract][Full Text] [Related]
39. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
40. Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.
Kohler PP; Volling C; Green K; Uleryk EM; Shah PS; McGeer A
Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1319-1328. PubMed ID: 28950924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]